Ten-year trends in benzodiazepine use in the Dutch population

Caroline M. Sonnenberg · Ellis J. M. Bierman · Dorly J. H. Deeg · Hannie C. Comijs · Willem van Tilburg · Aartjan T. F. Beekman

Abstract

Background In the past decades knowledge on adequate treatment of affective disorders and awareness of the negative consequences of long-term benzodiazepine use increased. Therefore, a decrease in benzodiazepine use is expected, particularly in prolonged use. The aim of this study was to assess time trends in benzodiazepine use.

Methods and material Data from the Longitudinal Aging Study Amsterdam (LASA) were used to investigate trends in benzodiazepine use between 1992 and 2002 in two population-based samples aged 55–64 years. Differences between the two samples with respect to benzodiazepine use and to sociodemographic, physical health and mental health characteristics were described and tested with chi-square tests and logistic regression analyses.

Results Benzodiazepine use remained stable over 10 years, with 7.8% in LASA-1 (n = 874) and 7.9% in LASA-2 (n = 919) (p = 0.90) with a persisting preponderance in women and in people with low education, low income, chronic physical diseases, functional limitations, cognitive impairment, depression, anxiety complaints, sleep problems and when using antidepressants. Long-term use remained high with 70% in 1992 and 80% in 2002 of total benzodiazepine use.

Conclusion In the Dutch population aged 55–64, overall benzodiazepine use remained stable from 1992 to 2002, with a high proportion of long-term users, despite the effort to reduce benzodiazepine use and the renewal of the guidelines. More effort should be made to decrease prolonged benzodiazepine use in this middle-aged group, because of the increasing risks with ageing.

Keywords Benzodiazepine use · Time trends · Population · Ageing

Introduction

Benzodiazepines are widely used in the treatment of anxiety complaints, nervousness and sleep problems [4, 16, 30, 33, 34]. Although people may benefit from their anxiolytic and hypnotic effects, when used for a longer period (more than 2 months) benzodiazepine use may lead to addiction problems, with withdrawal symptoms, diminishing effect and difficulty in discontinuing treatment [43]. Particularly in later life, benzodiazepines have serious adverse effects, such as an increased risk of mobility and ADL problems [25, 26], falling [15, 29, 45, 51] and a negative effect on cognitive functioning [5, 10, 27, 28, 46, 54]. They can cause sedation and impairment of driving skills [39]. Mental and physical health and cognitive performance improve after discontinuation of benzodiazepines, particularly sleeping pills [1]. Despite these known side-effects, benzodiazepines are widely used, also by middle-aged and older people and often for long periods of time [2, 4, 16, 22, 30, 33, 34, 37, 38]. Although dose escalation is rare in older people [14, 52], discontinuation of benzodiazepine use is found to be more difficult with ageing, particularly after 45 years [12, 13, 20].

In the past decades depression and anxiety disorders have gained a lot of attention, leading to increasing emphasis on the importance of adequate treatment of these
disorders. The newer generation of antidepressants, the selective serotonin reuptake inhibitors (SSRI’s), which are used in the treatment of depression as well as anxiety disorders, have become very popular and their use has shown a huge increase in the past decades [11, 40]. Also, the increasing knowledge of the impact of side effects and addiction problems of benzodiazepines has lead to the recommendation of short-term prescription and discontinuing use when possible, particularly in older people, with a preference for the short working benzodiazepines without pharmacologically active metabolites [28].

In the Dutch guidelines on pharmacological treatment of anxiety disorders serotonergic antidepressants are advised for pharmacological treatment. Benzodiazepines are recommended for short-term treatment only, in anxiety disorders as well as in mood disorders, with an exception of anxiety disorders that do not respond to two different SSRIs [3, 41]. Furthermore, in these years several types of psychotherapy have proven to be effective as well in anxiety and sleep disorders, e.g. exposure with response prevention and cognitive behaviour therapy, and they can be applied with or without pharmacotherapy [3, 49]. Thus, it might be expected that benzodiazepine use, and particularly long-term use, has decreased in the past years due to improved clinical practice. Another development that may have led to a decrease in benzodiazepine use is the increase of interest in and knowledge on physical and mental health issues in the general population in the past decades through the mass media and the more open communication. This has led to an increasing awareness of positive and negative consequences of drug use and an enhanced participation of patients in the process of medical decision-making.

In the literature, prevalence rates of benzodiazepine use vary between 2 and 17%, due to the variety in definitions of benzodiazepine use and observation period [60]. Conclusions on whether benzodiazepine use is stable in time are therefore not easily made. Consistent findings are that benzodiazepine use in women stays twice as high as in men, and that benzodiazepine use is higher in older people with a preponderance of long-term use [60].

**Objectives**

Our hypothesis is that in the past decades the development of special treatment for anxiety disorders, the introduction of SSRIs and the awareness of the addiction problems and the side effects of benzodiazepines have led to a decrease of benzodiazepine use, with a more adequate application and shorter use of benzodiazepines. We will investigate this in two population-based samples taking age, sex, income, education, physical problems, cognition, depression, anxiety, sleep problems, antidepressant use and alcohol use, into consideration. We chose this middle-aged group (55–64 years) because of the increasing risks of long-term benzodiazepine use when people grow older.

**Methods**

**Sampling and procedures**

Data were derived from the Longitudinal Aging Study Amsterdam (LASA), a longitudinal, interdisciplinary study on the predictors and consequences of changes in autonomy and well-being in the ageing population [18]. Baseline sampling procedures and characteristics of the sample have been described in detail in previous publications [6, 8, 17]. In short, the LASA sample is based on a representative random sample of 3,107 older adults between the ages of 55 and 85. The sample was drawn from the population registers of 11 municipalities in three regions of the Netherlands; each region consisted of one middle- to large-size city and two or more rural municipalities which bordered on the city, with numbers of inhabitants varying from 700,000 to 7,000 persons (n = 3,805, response rate 81.7%). The initial sample was stratified for age and sex and was weighted according to expected mortality at mid-term within each sex and age group, so that after 5 years equal numbers of men and women were expected to be alive in the separate age groups and that sufficient participants should be left to be examined after a period of 10 years. Non-response in the first LASA-cycle was related to age, but not to sex. Data-collection in LASA started in 1992–1993 (LASA-baseline) and participants were questioned every 3 years ever since. In 2002/2003 a new population sample was drawn, called LASA-2, by using the same sampling frame and procedures as for LASA-1. LASA-2 consisted of 1,002 respondents, with ages ranging from 55 to 64.

To address our research question, shifts in benzodiazepine use in 10 years, respondents of equal ages (55–64 years) from both samples were selected, resulting in 966 (LASA-1) and 1,002 (LASA-2) participants. Due to missing information on benzodiazepine use, samples of n = 874 (LASA-1) and 919 (LASA-2) were available for the analyses. In both samples this selection was not related to age, sex, or the other covariates.

All interviews were conducted in the homes of the respondents, by specially trained and intensively supervised interviewers. Informed consent was obtained from each respondent, according to the prevailing legal requirements. The study was approved by the Medical Ethical Committee of the VU University Medical Centre.
Measures

Use of benzodiazepines

Use of prescribed drugs was assessed in LASA-1 and LASA-2 by recording the medication from the drug containers in the homes of the respondents, and the duration of use was registered. The anatomical-therapeutical-chemical (ATC) coding and categorization system for drug data coding [44] was used to classify all medication. Benzodiazepines were categorised as tranquillisers agents (anxiolytics) or sleeping pills (hypnotics). Separate nominal variables were defined, indicating the use of anxiolytic drugs or hypnotic drugs (coded as ‘yes’ or ‘no’).

Duration of use was divided into four categories: short-term (<1 month), moderate (1 month–1 year), long-term (>1 year) and irregular (sometimes) use. When a respondent used more than one benzodiazepine, the longest use was counted.

The elimination time and the presence of pharmacologically active metabolites of the benzodiazepines were evaluated. The elimination time was considered long when half-life was >20 h. Presence (yes) or absence (no) of metabolites was established.

Covariates

Sex was investigated as a covariate, because of the preponderance of women in benzodiazepine use [23, 31, 42, 55, 57, 58], and in the prevalences of depression and anxiety disorders [32, 59].

Because socio-economic status is known to be associated with health status and health behaviour, and with benzodiazepine use [31, 55, 58], the level of education and the level of income were included as covariates.

The level of education was classified into three levels: low education (elementary school not completed, elementary education), medium education (lower vocational, general intermediate, intermediate vocational, general secondary education) and high education (higher vocational, college and university education).

Income was classified into three levels: low income (<1,000 Euros per month), intermediate income (1,000–3,000 Euros per month) and high income (more than 3,000 Euros per month). Income in LASA-1 was corrected for inflation of 3% per year until 2002.

Impaired physical health is associated with depression and anxiety complaints. Therefore, chronic diseases and functional limitations were included as independent variables.

Chronic diseases were assessed using specific questions on chronic non-specific lung disease, cardiac disease, peripheral atherosclerosis, stroke, diabetes mellitus, arthritis, malignant neoplasms and a maximum of two other chronic diseases. The total number of diseases ranged from 0 to 9. These data were cross-checked with the General Practitioners of the participants. Accuracy of self-report was shown to be independent of cognitive impairment, level of depressive symptoms and anxiety symptoms [36].

Functional limitations were measured with a questionnaire on difficulty experienced with several activities (walking up and down stairs, using public transportation and cutting own toenails). This questionnaire was validated in the Netherlands by Van Sonsbeek [50] and Kriegsman et al. [35].

Cognitive impairment might hamper recognition and treatment of affective disorders, but it can also be a side effect of benzodiazepine use. Cognitive impairment was measured with the Mini-Mental State Examination (MMSE), a frequently used screening instrument for global cognitive functioning. Scores range from 0 to 30 with higher scores indicating better cognitive performance. We used the cut-off score of 23, with scores ≤ 23 indicating cognitive impairment [21].

Excessive alcohol consumption may be an indication for addiction problems, but it can also be used as self-medication in the case of withdrawal symptoms in excessive benzodiazepine use. Alcohol consumption was assessed with a questionnaire developed for the Netherlands Health Interview Survey [53] and classified according to the Garretsen Index of Present Alcohol Use [24], into three categories (excessive/severe, moderate/light and non-drinker).

Depressive symptoms, anxiety symptoms and sleep problems, often the reason for benzodiazepine use, were measured with the Centre for Epidemiologic Studies Depression Scale (CES-D), a 20-item self-report scale developed for use in the community [7, 47, 48]. The CES-D ranges from 0 to 60 with higher scores indicating more depressive symptoms. The dichotomous score based on the commonly used cut-off score of 16 was used [9] to indicate clinically relevant depressive symptoms. Although the CES-D was designed for the screening of depressive symptoms, it may also be used as a screener of anxiety symptoms [7]. We used the particular CES-D item about feelings of nervousness and tension (item number 10: feeling fearful) to measure anxiety. To investigate sleep problems we used CES-D item number 11 (sleep being restless). This item had a good correlation with a larger questionnaire in LASA on sleep problems and could therefore be used as an indicator of sleep problems.

Antidepressant use was measured in the same way as benzodiazepine use, i.e. based on information on the drug containers, provided by the respondents. A separate nominal variable was defined, indicating the use of antidepressant drugs, coded as ‘yes’ or ‘no’.
Statistical analyses

In order to investigate time trends, i.e. changes over time in benzodiazepine use, the data had to be made suitable for comparing the two cycles. Therefore, prevalence data were weighted by age and sex, in order to reach a similar distribution of age and sex in the two study samples, with LASA-1 as the reference. To investigate the differences in benzodiazepine use between LASA-1 and LASA-2, i.e. to make a comparison between the two samples possible, we pooled the data from both samples and added the factor ‘time’ by defining the variable ‘sample number’ (1 = LASA-1 and 2 = LASA-2). In this pooled data file, first, for descriptive purposes, the differences between LASA-1 and LASA-2 with respect to benzodiazepine use and all covariates were tested using chi-square tests. Likewise, the differences between LASA-1 and LASA-2 within the groups of benzodiazepine users with respect to the covariates were tested using chi-square tests. In the pooled sample, associations of benzodiazepine use with the separate covariates were investigated in bivariate analyses using chi-square tests. To investigate the association of time and the other covariates with benzodiazepine use in a multivariate model, logistic regression analyses were performed, with benzodiazepine use as the dependent variable, and with time and the other covariates entered stepwise into the model. To investigate effect modification of the covariates on time differences in benzodiazepine use, logistic regression analyses with interaction-terms of time with the covariates were performed. In the chi-square tests and the logistic regression analyses, p values lower than 0.05 were regarded as statistically significant.

Results

An overview of the characteristics and the differences between LASA-1 and LASA-2 is shown in Table 1. Benzodiazepine use showed no major difference between the two samples with 7.8% in LASA-1 and 7.9% in LASA-2 (p = 0.90), nor did separate rates of tranquillising agents (3.7 and 4.8% resp., p = 0.24) and sleeping pills (4.6 and 3.9% resp, p = 0.49). In both samples the majority of the benzodiazepines was used for a long period. In LASA-1 26% was used during a month to a year, and 69% was used longer than 1 year. In LASA-2 these percentages were 15 and 80%. Use of short-working benzodiazepines without pharmacologically active metabolites increased from 56% in LASA-1 to 65% in LASA-2.

As a consequence of the weighing procedure, age and sex were equally distributed in the two samples. In LASA-1 47.9% were men and in LASA-2 47.2% were men.

Table 1 Socio-demographic characteristics, physical and mental health and benzodiazepine use in LASA-1 and LASA-2

|                | LASA-1 |        | LASA-2 |        | p value |
|----------------|--------|--------|--------|--------|---------|
|                | N = 874| %      | N = 919| %      |         |
| Education      |        |        |        |        |         |
| Low            | 268    | 30.7   | 188    | 20.5   | 0.00    |
| Intermediate   | 479    | 54.8   | 532    | 57.9   |         |
| High           | 127    | 14.5   | 199    | 21.7   |         |
| Incomea        |        |        |        |        |         |
| Low            | 135    | 18.9   | 100    | 11.9   | 0.00    |
| Medium         | 370    | 51.7   | 365    | 43.5   |         |
| High           | 211    | 29.5   | 375    | 44.6   |         |
| Chronic diseases|       |        |        |        |         |
| None           | 310    | 35.5   | 243    | 26.4   | 0.00    |
| One or more    | 564    | 64.5   | 676    | 73.6   |         |
| Functional limitations (of #3) | | | | | |
| None           | 725    | 83.0   | 667    | 72.6   | 0.00    |
| One or more    | 149    | 17.0   | 252    | 27.4   |         |
| Cognitive impairment | | | | | |
| No: MMSE ≥23   | 848    | 97.0   | 888    | 96.6   | 0.52    |
| Yes: MMSE ≥23  | 26     | 3.0    | 31     | 3.4    |         |
| Depression     |        |        |        |        |         |
| No             | 781    | 89.4   | 790    | 86.0   | 0.03    |
| Yes (CESD ≥16) | 93     | 10.6   | 129    | 14.0   |         |
| Anxiety: being fearful | | | | | |
| No             | 785    | 89.8   | 803    | 87.4   | 0.16    |
| Sometimes—often| 89     | 10.2   | 116    | 12.6   |         |
| Sleep problems |        |        |        |        |         |
| Never/some of the time | 753  | 86.2  | 758    | 82.5   | 0.03    |
| Occasionally often—always | 121  | 13.8  | 161    | 17.5   |         |
| Use of alcohol |        |        |        |        |         |
| Never          | 129    | 14.8   | 75     | 8.2    | 0.00    |
| Light—moderate | 683    | 78.1   | 744    | 80.9   |         |
| (very) excessive| 62    | 7.1    | 100    | 10.9   |         |
| Antidepressant users | | | | | |
| No             | 861    | 98.5   | 883    | 96.1   | 0.00    |
| Yes            | 13     | 1.5    | 36     | 3.9    |         |
| Benzodiazepine users |      |        |        |        |         |
| All            | 68     | 7.8    | 73     | 7.9    | 0.90    |
| Anxiolytic users | 32    | 3.7    | 44     | 4.8    | 0.24    |
| Hypnotic users | 40     | 4.6    | 36     | 3.9    | 0.49    |
| Length of benzodiazepine useb | | | | | |
| Short term (<1 month) | 3     | 5.5    | 4      | 5.5    | 0.34    |
| Moderate (1 month–1 year) | 14  | 25.5   | 11     | 15.1   |         |
| Long term (>1 year) | 38   | 69.1   | 58     | 79.5   |         |
| Long half-life and/or active metabolites of benzodiazepines | | | | | |
| No             | 38     | 55.9   | 47     | 64.4   | 0.30    |
| Yes            | 30     | 44.1   | 26     | 35.6   |         |

a In the questionnaire about income, respondents were able to choose the option ‘wishes not to answer’; this resulted in ‘no answer’ in 158 respondents (18.1%) in LASA-1 and in 79 respondents (8.6%) in LASA-2. This category was left out of the analyses

b In LASA-1 duration of benzodiazepine use was not known in 13 respondents (19.1%), leaving 55 out of 68 benzodiazepine users available for the analyses in length of benzodiazepine use
In the present study shifts in benzodiazepine use from 1992 to 2002 were investigated in a population-based sample aged 55–64 years. The second sample was higher educated and had a higher income despite the inflation correction. Furthermore, respondents in LASA-2 reported more chronic diseases and functional limitations, and showed more depressive symptoms. They also reported more sleep problems. The presence of cognitive impairment and anxiety symptoms remained rather stable in the two samples. In LASA-2 more respondents used alcohol and there was also a rise in the amount of alcohol used. Furthermore, there was a remarkable increase of antidepressant use.

Table 2 shows time differences in benzodiazepine use in the socio-demographic and health subgroups and associations of benzodiazepine use with these subgroups in the pooled sample. Although an increase of benzodiazepine use was found in several subgroups (e.g. in women, in respondents with low education or low income, and in the case of depression, anxiety and sleep problems) and a decrease in other subgroups (e.g. men, high education, high income, and antidepressant users), these differences were not statistically significant, probably due to the small numbers in several subgroups.

In the pooled sample, benzodiazepine use was significantly higher in women, and in the respondents with chronic physical disease, functional limitations, cognitive impairment, depression, anxiety, sleep problems and when using an antidepressant. Benzodiazepine use was lower in respondents with higher education, higher income and with higher alcohol use.

Table 3 shows the odds ratios for benzodiazepine use and time and the other covariates. The bivariate logistic regression analyses showed statistically significant associations of benzodiazepine use all covariates, but not with time and age. In the multivariate regression analyses, controlling for all covariates including time, benzodiazepine use was found to be associated with female sex, and with the presence of one or more chronic diseases, depression, sleep problems and antidepressant use.

Investigation of the interaction between time and the independent variables did not show any statistically significant interaction (results not shown).

Discussion

In the present study shifts in benzodiazepine use from 1992 to 2002 were investigated in a population-based sample aged 55–64 years.

We expected a decrease of benzodiazepine use due to enhanced knowledge of the effects of long-term benzodiazepine use and insight into adequate treatment of depression, anxiety and sleep problems. However, benzodiazepine use remained stable. Furthermore, long-term use remained high despite recommendations in the guidelines to keep treatment short. However, compared with the increase of antidepressant use in this period, the stability in benzodiazepine use may be considered a relatively positive finding. A trend in preference was found for short-working benzodiazepines without pharmacological active metabolites, which is also a positive finding in this middle-aged group.

In our study, several socio-demographic characteristics and physical health and mental health factors that are known to be associated with benzodiazepine use showed differences in the two samples. We found a decrease in the prevalence of low income and low education, and an increase in the prevalence of physical health problems, depression, sleep problems, alcohol use and antidepressant use. However, the shifts in the presence of these characteristics and risk factors did not affect their associations with benzodiazepine use, nor did age or sex: all factors except time and age were associated with benzodiazepine use. This is in line with the literature. Being a woman, having one or more chronic diseases, depression, sleep problems and the use of antidepressant remained associated with benzodiazepine use in the multivariate analyses and were considered to explain the association with the other risk factors.

In 2002, women and respondents with low education still used more benzodiazepines. Respondents with chronic physical disease and functional limitations still used more benzodiazepines. Although they may diminish feelings of distress and sleep problems, they can also cause sedation, muscle weakness and increase the risk of falling in this physically vulnerable group. In the respondents with cognitive impairment, benzodiazepines are often used successfully to reduce concomitant anxiety and sleep disturbances, but they may increase memory problems and reduce attention, alertness and mental speed. In the case of depression, anxiety and sleep problems, benzodiazepine use remained high, although it is recommended only for short-term use or for support in the first weeks of treatment with antidepressants or psychotherapy. Prolonged use of benzodiazepines may even worsen the depressive symptoms.

The combination of benzodiazepine use and the use of alcohol is important because of the possibility of excessive sedation and mood disturbances. In the alcohol users benzodiazepine use was lower than in the full sample, but some respondents combined alcohol with benzodiazepine, which may lead to important health problems, e.g. a higher risk of falling, memory problems and traffic accidents, particularly when this group gets older.
Table 2 Benzodiazepine use by socio-demographic and health measures in LASA-1 and LASA-2 and in the pooled sample (LASA 1 + 2)

| Subgroups | LASA-1 N = 874 | LASA-2 N = 919 | Time differences for the subgroups p value | LASA 1 + 2 pooled sample N = 1,793 | Subgroup differences (in pooled sample) p value |
|-----------|----------------|----------------|----------------------------------------|-----------------------------------|---------------------------------|
| Benzodiazepine users | N % in subgroup | Benzodiazepine users | N % in subgroup | N % in subgroup | N % in subgroup |
| Sex       |                |                |                         |                                   |                                |
| Men       | 21 5.0        | 14 3.2         | 0.19                    | 35 4.1                            | 0.00                           |
| Women     | 47 10.3       | 59 12.2        | 0.37                    | 106 11.3                          |                                |
| Education |                |                |                         |                                   |                                |
| Low       | 25 9.3        | 22 11.7        | 0.41                    | 47 10.3                           | 0.02                           |
| Intermediate | 34 7.1      | 44 8.3         | 0.49                    | 78 7.7                            |                                |
| High      | 9 7.1         | 7 3.5          | 0.15                    | 16 4.9                            |                                |
| Income    |                |                |                         |                                   |                                |
| Low       | 16 11.9       | 15 15.0        | 0.48                    | 31 13.2                           | 0.00                           |
| Medium    | 23 6.2        | 27 7.4         | 0.53                    | 50 6.8                            |                                |
| High      | 15 7.1        | 22 5.9         | 0.55                    | 37 6.1                            |                                |
| Chronic diseases |            |                |                         |                                   |                                |
| None      | 12 3.9        | 8 3.3          | 0.72                    | 20 3.6                            | 0.00                           |
| One or more | 56 9.9     | 65 9.6         | 0.85                    | 121 9.8                           |                                |
| Functional limitations |          |                |                         |                                   |                                |
| None      | 46 6.3        | 40 6.0         | 0.79                    | 86 6.2                            | 0.00                           |
| One or more | 22 14.8   | 33 13.1        | 0.64                    | 55 13.7                           |                                |
| Cognitive impairment |        |                |                         |                                   |                                |
| No: MMSE >23 | 63 7.4    | 67 7.5         | 0.93                    | 130 7.5                           | 0.00                           |
| Yes: MMSE ≤23 | 5 19.2  | 6 19.4         | 0.99                    | 11 19.3                           |                                |
| Depression |                |                |                         |                                   |                                |
| No (CESD <16) | 47 6.0  | 42 5.3         | 0.55                    | 89 5.7                            | 0.00                           |
| Yes (CESD ≥16) | 21 22.6 | 31 24.0        | 0.80                    | 52 23.4                           |                                |
| Anxiety: being fearful |          |                |                         |                                   |                                |
| No        | 53 6.8        | 49 6.1         | 0.60                    | 102 6.4                           | 0.00                           |
| Sometimes—often | 15 16.9 | 24 20.7        | 0.49                    | 39 19.0                           |                                |
| Sleep problems |            |                |                         |                                   |                                |
| Never—sometimes | 47 6.2 | 36 4.7         | 0.20                    | 83 5.5                            | 0.00                           |
| Occasionally often—always | 21 17.4 | 37 23.0 | 0.25 | 58 20.6 |                                |
| Use of alcohol |            |                |                         |                                   |                                |
| Never     | 15 11.6       | 12 16.0        | 0.37                    | 27 13.2                           | 0.00                           |
| Light—moderate | 51 7.5   | 56 7.5         | 0.97                    | 107 7.5                           |                                |
| (very) Excessive | 2 3.2   | 5 5.0          | 0.59                    | 7 4.3                            |                                |
| Antidepressant use |        |                |                         |                                   |                                |
| No        | 62 7.2        | 63 7.1         | 0.96                    | 125 7.2                           | 0.00                           |
| Yes       | 6 46.2        | 10 27.8        | 0.23                    | 16 32.7                           |                                |

Strength and limitations of the study

There are some limitations to this study. Access to two large population-based samples with data concerning a wide variety of relevant variables makes LASA very well suited for an investigation of trends in benzodiazepine use. However, within specific subgroups, the numbers using benzodiazepines were small, which limits statistical analyses in subgroups. A second limitation of the present study is the use of self-reports. This may cause report bias, due to problems in the recall of information from the past (chronic disease), or to unwillingness or feelings of shame (income,

© Springer
education, alcohol use). However, the main variable in this study, medication use, was recorded directly from the containers and did not rely on self-report.

### Conclusion

It was concluded that benzodiazepine use in this middle-aged population sample remained stable from 1992 to 2002, with a majority of long-term use, despite recommendations in the guidelines for short-term use. Benzodiazepine use remained higher in women, and in respondents with low education, low income, chronic physical disease, functional limitations, depression, anxiety complaints, sleep problems and in those using an antidepressant. More attention should be paid to reduce benzodiazepine use in the middle-aged, in order to diminish its increasing negative effects on health and functioning when getting older. In the case of long-term use, discontinuation programmes with a tapering-off procedure may be helpful.

### Acknowledgments

The data reported on were collected in the context of the Longitudinal Aging Study Amsterdam, which is financed primarily by the Netherlands Ministry of Welfare, Health and Sports. We want to thank our professional research assistant Jan Poppeliers and the Dutch older people that participated in the LASA-study.

### Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

### References

1. Ashton H (2005) The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 18:249–255
2. Balestrieri M, Bortolomasi M, Galletta M, Bellantuono C (1997) Patterns of hypnotic drug prescription in Italy. A two-week community survey. Br J Psychiatry 170:176–180
3. Van Balkom AJLM, Van Dyck R, Van Megen HJM, Timmerman L, Van Vliet IM, Westenberg HGM (1998) Richtlijn farmacotherapie angststoornissen. Nederlandse Vereniging voor Psychiatrie, Boom, Amsterdam
4. Barbee JG (1993) Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives. J Clin Psychiatry 54:86–97
5. Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004) Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 18:37–48
6. Beekman AT, Geerlings SW, Deeg DJH, Smit HH, Schoevers RS, de Beurs E, Braam AW, Penninx BWJH, van Tilburg W (2002) The natural history of late-life depression: a 6-year prospective study in the community, Arch Gen Psychiatry 59:605–611
7. Beekman AT, Deeg DJH, van Limbeek J, Braam AW, de Vries MZ, van Tilburg W (1997) Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): results from a community-based sample of older subjects in The Netherlands. Psychol Med 27:231–235
8. Beekman AT, Deeg DJH, van Tilburg T, Smit JH, Hooijer C, van Tilburg W (1995) Major and minor depression in later life: a study of prevalence and associated factors. J Affect Disord 36:65–75
9. Berkman LF, Berkman CS, Kasl S, Freeman DH Jr, Leo L, Ostfeld AM, Cornoni-Huntley J, Brody JA (1986) Depressive symptoms in relation to physical health and functioning in the elderly. Am J Epidemiol 124:372–388
10. Bierman EJ, Comijs HC, Gundy CM, Sonnenberg C, Jonker C, Beekman AT (2007) The effects of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent? Int J Geriatr Psychiatry 22:1194–1200
11. Brugh TS, Bebbington PE, Singleton N, Meltzer D, Jenkins R, Lewis G, Farrell M, Bhugra D, Lee A, Meltzer H (2004) Trends in service use and treatment for mental disorders in adults throughout Great Britain. Br J Psychiatry 185:378–384
12. Cans C, Rotilé M (1991) Consumption of psychotropic drugs in the general population in the Isere-district. Rev Epidemiol Sante Publique 39:515–522
13. Cook JM, Biyanova T, Masci C, Coyne JC (2007) Patient perspectives on long-term anxiolytic benzodiazepine use and discontinuation: a qualitative study. J Gen Intern Med 22:1094–1100
14. Cook JM, Marshall R, Maxci C, Coyne JC (2007) Physicians’ perspectives on prescribing benzodiazepines for older adults: a qualitative study. J Gen Intern Med 22:303–307
15. Cumming RG, Le Couteur DG (2003) Benzodiazepines and risk of hip fractures in older people: review of the evidence. CNS Drugs 17:825–837
16. Curran HV (1991) Benzodiazepines, memory and mood: a review. Psychopharmacology 105:1–8

---

**Table 3** Odds Ratios with 95% CI for benzodiazepine use and time, sociodemographic and health measures, unadjusted and adjusted for all co-variates, in the pooled sample

|                  | Unadjusted | Adjusted |
|------------------|------------|----------|
| **OR**           | **95% CI** | **OR**   | **95% CI** |
| Time             | 1.02       | 0.73–1.44| 0.80       | 0.54–1.18 |
| Female sex       | 2.97       | 2.00–4.41| 2.31       | 1.50–3.57 |
| Older age group  | 1.09       | 0.77–1.54| 1.00       | 0.69–1.45 |
| Higher education | 0.69       | 0.53–0.90| 0.95       | 0.70–1.30 |
| Higher income    | 0.79       | 0.68–0.94| 0.99       | 0.82–1.20 |
| One or more chronic diseases | 2.88   | 1.78–4.68| 1.86   | 1.11–3.10 |
| One or more functional limitations | 2.41  | 1.69–3.46| 1.26   | 0.82–1.93 |
| Cognitive impairment | 2.95   | 1.50–5.84| 1.70   | 0.77–3.80 |
| Depression       | 5.09       | 3.49–7.43| 2.28       | 1.43–3.64 |
| Anxiety          | 3.42       | 2.29–5.12| 1.38       | 0.86–2.24 |
| Sleep problems   | 4.46       | 3.10–6.41| 2.29       | 1.50–3.50 |
| Use of alcohol   | 0.54       | 0.37–0.78| 0.83       | 0.55–1.26 |
| Antidepressant use | 6.28  | 3.36–11.72| 3.71  | 1.83–7.52 |
18. Deeg DJH, Westendorp-de Seriere M (1994) Autonomy and well-being in the aging population. Report from the Longitudinal Aging Study Amsterdam 1992–1993. VU University Press, Amsterdam.

19. Dhondt ADF, Derksen P, Hooijer C, Heycop van, Ham B ten, Gent PP van, Heeren T (1999) Depressogenic medication as an aetiological factor in major depression. An analysis in a clinical population of depressed elderly people. Int J Geriatr Psychiatry 14:875–881.

20. Dunbar GC, Perera MH, Jenner FA (1989) Patterns of benzodiazepine use in Great Britain as measured by a general population survey. Br J Psychiatry 155:836–841.

21. Folstein MF, Folstein SE, McHugh PR (1975) A practical method for the clinician. J Psychiatr Res 12:189–198.

22. Forsell Y, Winblad B (1997) Psychiatric disturbances and the use of psychotropic drugs in a population of nonagenarians. In J Geriatr Psychiatry 12:533–136.

23. Fortin D, Previll M, Ducharme C, Hebert R, Trottier L, Gregoire J, Allard J, Berard A (2007) Factors associated with long-term benzodiazepine use among elderly women and men in Quebec. J Women Aging 19:37–52.

24. Garretsen HFL (1983) Problem drinkers. Swets & Zeitlinger, Lisse.

25. Gray SL, LaCroix AZ, Hanlon JT, Penninx BWJH, Blough DK, Leveille SG, Arzt MB, Guralnik JM, Buchner DM (2006) Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc 54:224–230.

26. Gray SL, Penninx BWJH, Blough DK, Arzt MB, Guralnik JM, Wallace RB, Buchner DM, LaCroix AZ (2003) Benzodiazepine use and physical performance in community-dwelling older women. J Am Geriatr Soc 51:1563–1570.

27. Hanlon JT, Horner RD, Schmader KE, Fillenbaum GG, Lewis IK, Wall WE Jr, Landerman LR, Pieper CF, Blazer DG, Cohen HJ (1998) Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther 64:684–692.

28. Hogan DB, Maxwell CJ, Fung TS, Eby EM (2003) Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian Study of Health and Aging. Can J Clin Pharmacol 10:72–77.

29. Huisman MAR, Schoofs MW, Ziere G, Hofman A, Pols HA, Sturkenboom MC, Stricker BH (2008) Inappropriate benzodiazepine use in older adults and the risk of fracture. Br J Clin Pharmacol 66:276–282.

30. Jorm AF, Grayson D, Creasey H, Waite L, Broe GA (2000) Long-term benzodiazepine use by elderly people living in the community. Aust N Z J Public Health 24:7–10.

31. Kassam A, Patten SB (2006) Hypnotic use in a population-based sample of over thirty-five thousand interviewed Canadians. Popul Health Metr 4:1–15.

32. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB (1993) Sex and depression in the National Comorbidity Survey I: lifetime prevalence, chronicity and recurrence. J Affect Disord 29:85–96.

33. King MB (1994) Long-term benzodiazepine users—a mixed bag. Addiction 89:1367–1370.

34. Kirby M, Denihan A, Bruce I, Radic A, Coakley D, Lawlor BA (1999) Benzodiazepine use among the elderly in the community. Int J Geriatr Psychiatry 14:280–284.

35. Kriegsman DMW, Deeg DJH, van Eijk JT, Penninx BWJH, Boeke AJ (1997) Do disease specific characteristics add to the explanation of mobility limitations in patients with different chronic diseases? A study in The Netherlands. J Epidemiol Community Health 51:676–685.

36. Kriegsman DM, Penninx BW, van Eijk JT, Boeke AJ, Deeg DJH (1996) Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients’ self-reports and on determinants of inaccuracy. J Clin Epidemiol 49:1407–1417.

37. Laguana R, Depont F, Fourrier A, Abouelfath A, Begaud B, Verdoux H, Moore N (2004) Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 60:523–529.

38. Luijendijk HJ, Tiemeler H, Hofman A, Heerenga J, Stricker BH (2008) Determinants of chronic benzodiazepine use in the elderly: a longitudinal study. Br J Clin Pharmacol 65:593–599.

39. Madhusoodanan S, Bagnouvis OJ (2004) Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf 3:485–493.

40. van Marwijk HWJ, Bijl D, Ader HJ, de Haan M (2001) Antibispressant prescription for depression in general practice in the Netherlands. Pharm World Sci 23:46–49.

41. Neomagus GJH, Terluin B, Aulbers LPI, Hekman J, van Heest FB, van der Meer K (1997) NHG-staandaard angststoornissen. Huisarts Wet 40:167–175.

42. Neutel CI (2005) The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 17:189–197.

43. Oude Voshaar RC, Couvee JE, van Balkom AJ, Mulder PG, Zitman FG (2006) Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry 189:213–220.

44. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P (1994) Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 10:405–411.

45. Pariente A, Dartigues JF, Benichou J, Letenneur L, Moore N, Fourrier-Reglat A (2008) Benzodiazepines and injuries and falls in community dwelling elders. Drugs Aging 25:61–70.

46. Pat McAndrews M, Weiss RT, Sandor P, Taylor A, Carlen PL, Shapiro CM (2003) Cognitive effects of long-term benzodiazepine use in older adults. Hum Psychopharmacol 18:51–57.

47. Radloff LS, Teri L (1986) Use of the CES-D with older adults. Clin Gerontol 5:119–136.

48. Radloff LS (1977) The CES-D scale: a self-report depression scale for research in general population. Appl Psychol Meas 3:385–401.

49. Riemann D, Perlis ML (2009) The treatments of chronic insomnia: a review of benzodiazepine receptor antagonists and pharmacological and psychological therapies. Sleep Med Rev 13:205–214.

50. van Sonsbeek JLA (1988) Methodological and substantial aspects of the OECD indicator of chronic functional limitations. Mandebrief Gezondheid (CBS) 88:4–17.

51. Sorock GS, Shimkin EE (1988) Benzodiazepine sedatives and the risk of falling in a community-dwelling elderly cohort. Arch Intern Med 148:2441–2444.

52. Soumerai SB, Simoni-Wastila L, Singer C, Mah C, Gao X, Saltzman C, Ross-Degnan D (2003) Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr Serv 54:1006–1011.

53. Statistical Yearbook (1993). Central Bureau of Statistics (CBS), Den Haag.

54. Stewart SA (2005) The effects of benzodiazepines on cognition. J Clin Psychiatry 66(suppl 2):9–13.

55. Swartz M, Landerman R, George LK, Melville ML, Blazer D, Carbonin P (1994) Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 10:405–411.

56. van Vliet P, van der Mast RC, van den Broek M, Westendorp RG, de Craen AJ (2008) Use of benzodiazepines, depressive symptoms and cognitive function in old age. Int J Geriatr Psychiatry (published online).
57. van der Waals FW, Mohrs J, Foets M (1993) Sex differences among recipients of benzodiazepines in Dutch general practice. Br Med J 307:363–366

58. Wells KB, Kamberg C, Brook R, Camp P, Rogers W (1985) Health status, sociodemographic factors, and the use of prescribed psychotropic drugs. Med Care 23:1295–1306

59. Weissman MM, Leaf PJ, Holzer CE, Meyers JK, Tischler GL (1984) The epidemiology of depression. An update on sex differences in rates. J Affect Disord 7:179–188

60. Zandstra SM, Furer JW, van de Lisdonke EH, Bor JHJ, van Weel C, Zitman FG (2002) Different study criteria affect the prevalence of benzodiazepine use. Soc Psychiatry Psychiatr Epidemiol 37:139–144